Biomarin Pharmaceutical Inc at Cowen HealthCare Conference Transcript
Good morning, and welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. It's my pleasure to introduce the next presenting company, that's BioMarin. We have CEO, J.J. Bienaimé here with us today. He's going to give a corporate update with about 8 or 10 slides, and then he and I are going to have a Q&A session following. J.J.? Thank you.
©,-&
Thank you, Phil. Good morning, everybody. Just want to highlight, as usual, that this presentation will contain forward-looking statements. For details about this, look at our 10-K, 10-Q and 8-K reports.
So I think most of you in the room are pretty familiar with the company. But in terms of overall mission of the company, we are entirely focused on rare and serious genetic disorders, most of them life-threatening.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
